Pirfenidone in idiopathic pulmonary fibrosis

Drugs of Today

Volumn 46, Issue 7, 2010, Pages 473-482

  Maher, Toby M ^a,b,c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; ESBRIET; PIRFENIDONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ANOREXIA; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DIZZINESS; DOWN REGULATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GENETIC TRANSCRIPTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; LUNG FUNCTION; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PHOTODERMATOSIS; PHOTOSENSITIVITY DISORDER; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL; VALIDATION PROCESS; VOMITING;

EID: 77958165170     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.7.1488336     Document Type: Review

References (56)

1. Maher, T.M. The diagnosis of idiopathic pulmonary fibrosis and its complications. Expert Opin Med Diagn 2008, 2(12): 1317-31.
2. Maher, T.M., Wells, A.U., Laurent, G.J. Idiopathic pulmonary fibrosis: Multiple causes and multiple mechanisms? Eur Respir J 2007, 30(5): 835-9.
3. Bowen, J.D., Maravilla, K., Margolin, S.B. Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis. Mult Scler 2003, 9(3): 280-3. (Pubitemid 36681894)
4. Cho, M.E., Smith, D.C., Branton, M.H., Penzak, S.R., Kopp, J.B. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007, 2(5): 906-13.
5. Walker, J.E., Giri, S.N., Margolin, S.B. A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. Mult Scler 2005, 11(2): 149-58.
6. Angulo, P., MacCarty, R.L., Sylvestre, P.B. Jorgensen, R.A., Wiesner, R.H., LaRusso, N.A., Lindor, K.D. Pirfenidone in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2002, 47(1): 157-61. (Pubitemid 34075033)
7. Armendariz-Borunda, J., Islas-Carbajal, M.C., Meza-Garcia, E. et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 2006, 55(11): 1663-5. (Pubitemid 44629221)
8. Mesa, R.A., Tefferi, A., Elliott, M.A. et al. A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia. Br J Haematol 2001, 114(1): 111-3. (Pubitemid 32702642)
9. Kaneko, M., Inoue, H., Nakazawa, R. et al. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin Exp Immunol 1998, 113(1): 72-6. (Pubitemid 28329068)
10. Nakayama, S., Mukae, H., Sakamoto, N. et al. Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci 2008, 82(3-4): 210-7.
11. Chen, J.J., Zhao, S., Cen, Y., Liu, X.X., Yu, R., Wu, D.M. Effect of heat shock protein 47 on collagen accumulation in keloid fibroblast cells. Br J Dermatol 2007, 156(6): 1188-95. (Pubitemid 47029833)
12. Lee, B.S., Margolin, S.B., Nowak, R.A. Pirfenidone: A novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab 1998, 83(1): 219-23.
13. Di, S.A., Bendia, E., Svegliati, B.G. et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol 2002, 37(5): 584-91. (Pubitemid 35305537)
14. Nakazato, H., Oku, H., Yamane, S.,Tsuruta, Y., Suzuki, R. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol 2002, 446(1-3): 177-85. (Pubitemid 34722572)
15. Oku, H., Nakazato, H., Horikawa, T., Tsuruta, Y., Suzuki, R. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 2002, 446(1-3): 167-76. (Pubitemid 34722571)
16. Cain, W.C., Stuart, R.W., Lefkowitz, D.L., Starnes, J.D., Margolin, S., Lefkowitz, S.S. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol 1998, 20(12): 685-95. (Pubitemid 28540774)
17. Hale, M.L., Margolin, S.B., Krakauer, T. Roy, C.J., Stiles, B.G. Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B. Infect Immun 2002, 70(6): 2989-94.
18. Giri, S.N., Leonard, S., Shi, X., Margolin, S.B., Vallyathan, V. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol 1999, 18(3): 169-77.
19. Misra, H.P., Rabideau, C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem 2000, 204(1-2): 119-26. (Pubitemid 30111765)
20. Mitani, Y., Sato, K., Muramoto, Y. et al. Superoxide scavenging activity of pirfenidone-iron complex. Biochem Biophys Res Commun 2008, 372(1): 19-23. (Pubitemid 351778163)
21. Maher, T.M., Wells, A.U. Lost in translation; From animal models of pulmonary fibrosis to human disease. Respirology 2009, 14(7): 915-6.
22. Iyer, S.N., Wild, J.S., Schiedt, M.J., Hyde, D.M., Margolin, S.B., Giri, S.N. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 1995, 125(6): 779-85.
23. Iyer, S.N., Margolin, S.B., Hyde, D.M., Giri, S.N. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp Lung Res 1998, 24(1): 119-32.
24. Kehrer, J.P., Margolin, S.B. Pirfenidone diminishes cyclophosphamide- induced lung fibrosis in mice. Toxicol Lett 1997, 90(2-3): 125-32.
25. Card, J.W., Racz, W.J., Brien, J.F., Margolin, S.B., Massey, T.E. Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. Toxicol Sci 2003, 75(1): 169-80.
26. Kakugawa, T., Mukae, H., Hayashi, T. et al. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J 2004, 24(1): 57-65. (Pubitemid 39029069)
27. Moeller, A., Ask, K., Warburton, D., Gauldie, J., Kolb, M. The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008, 40(3): 362-82.
28. Spond, J., Case, N., Chapman, R.W. et al. Inhibition of experimental acute pulmonary inflammation by pirfenidone. Pulm Pharmacol Ther 2003, 16(4): 207-14. (Pubitemid 36798118)
29. Mei, S., Yao, W., Zhu, Y. et al. Protection of pirfenidone against on early phase of oleic acid-induced acute lung injury in rats. J Pharmacol Exp Ther 2005, 313(1): 379-88.
30. Iyer, S.N., Hyde, D.M., Giri, S.N. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation 2000, 24(5): 477-91.
31. Oku, H., Shimizu, T., Kawabata, T. et al. Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008, 590(1-3): 400-8.
32. Iyer, S.N., Gurujeyalakshmi, G., Giri, S.N. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999, 291(1): 367-73.
33. Gurujeyalakshmi, G., Hollinger, M.A., Giri, S.N. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 1999, 276(2, Pt. 1): L311-L318. (Pubitemid 29102273)
34. Iyer, S.N., Gurujeyalakshmi, G., Giri, S.N. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999, 289(1): 211-8.
35. Giri, S.N., Wang, Q., Xie, Y., Lango, J., Morin, D., Margolin, S.B., Buckpitt, A.R. Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. Biopharm Drug Dispos 2002, 23(5): 203-11.
36. Shi, S., Wu, J., Chen, H., Chen, H., Wu, J., Zeng, F. Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol 2007, 47(10): 1268-76.
37. Rubino, C.M., Bhavnani, S.M., Ambrose, P.G., Forrest, A., Loutit, J.S. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 2009, 22(4): 279-85.
38. Babovic-Vuksanovic, D., Widemann, B.C., Dombi, E. et al. Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas. Pediatr Neurol 2007, 36(5): 293-300.
39. Taniyama, M., Ohbayashi, S., Narita, M. et al. Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients. Eur J Clin Pharmacol 1997, 52(1): 77-8.
40. Raghu, G., Brown, K.K., Bradford, W.Z. et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004, 350(2): 125-33.
41. Martinez, F.J., Safrin, S., Weycker, D. et al. The clinical course of patients with Idiopathic pulmonary fibrosis. Ann Intern Med 2005, 142(12, Pt. 1): 963-7.
42. Collard, H.R., Moore, B.B., Flaherty, K.R. et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007, 176(7): 636-43.
43. Du Bois, R.M. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010, 9(2): 129-40.
44. Latsi, P.I., du Bois, R.M., Nicholson, A.G. et al. Fibrotic idiopathic interstitial pneumonia: The prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003, 168(5): 531-7.
45. Wells, A.U., Desai, S.R., Rubens, M.B. et al. Idiopathic pulmonary fibrosis: A composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003, 167(7): 962-9.
46. Zappala, C.J., Latsi, P.I., Nicholson, A.G. et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35(4): 830-6.
47. Swigris, J.J., Wamboldt, F.S., Behr, J., du Bois, R.M., King, T.E., Raghu, G., Brown, K.K. The 6 minute walk in idiopathic pulmonary fibrosis: Longitudinal changes and minimum important difference. Thorax 2010, 65(2): 173-7.
48. Garin, M.C., Highland, K.B., Silver, R.M., Strange, G. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol 2009, 36(2): 330-6.
49. Raghu, G., Johnson, W.C., Lockhart, D., Mageto, Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999, 159(4, Pt. 1): 1061-9.
50. Nagai, S., Hamada, K., Shigematsu, M., Taniyama, M., Yamauchi, S., Izumi, T. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002, 41(12): 1118-23.
51. Gahl, W.A., Brantty, M., Troendle, J. et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 2002, 76(3): 234-42.
52. Moises, S., Girod, C.E., Shifren, A. et al. A double-blind, multicenter study comparing pirfenidone and prednisone for moderate-to-severe pulmonary fibrosis. Chest 2003, 124(4): 116S-b.
53. Azuma, A., Nukiwa, T., Tsuboi, E. et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005, 171(9): 1040-7.
54. Mathai, S.C., Polito, A.J. The questionable efficacy of pirfenidone in IPF. Am J Respir Crit Care Med 2005, 172(9): 1228.
55. Taniguchi, H., Ebina, M., Kondoh, Y. et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010, 35(4): 821-9.
56. Noble, P., Albera, C., Bradford, W. et al. The CAPACITY (CAP) Trials: Randomized, double-blind, placebo-controlled, phase III trials of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med 2009, 179: A1129.